3:18 PM
 | 
Oct 11, 2017
 |  BC Extra  |  Clinical News

Ardelyx planning NDA for IBS-C candidate

Ardelyx Inc. (NASDAQ:ARDX) plans to submit an NDA to FDA in 2H18 for tenapanor (RDX5791) to treat irritable bowel syndrome with constipation after it said Wednesday that the compound met the primary and secondary endpoints in the Phase III T3MPO-2 trial. Ardelyx shares were up $1.60 (30%) to $7 in early after-hours trading.

On the 593-patient trial's primary endpoint, twice-daily 50 mg tenapanor for 26 weeks led to...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >